Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2029-02-01
Target enrollment:
Participant gender:
Summary
This is a prospective, multi-center, single-arm, phase 2 study aiming to assess the efficacy
and safety of adjuvant use of Ensartinib in stage IB-IIIA non-small cell lung cancer (NSCLC)
with positive ALK-fusion. Enrolled patients will take Ensatinib for 3 years or until
recurrence of the disease or intolerable toxicity, following complete tumour resection with
or without adjuvant standard chemotherapy.